Technology Transactions and Licensing

Technology Transactions and Licensing

We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

Key Contacts

Meet Our Team

Areas of Focus

Expand All Collapse All


  • Represented Hilton in an exclusive co-branded credit card partnership agreement with American Express, beginning January 1, 2018. The agreement follows a comprehensive and competitive bidding process aimed at creating long-term value for both companies, hotel owners, guests and Hilton Honors members. The terms of the new multi-year partnership remain confidential.
  • Represented Vividion Therapeutics, a biotechnology company using novel proteomics and chemistry platforms, in a strategic research collaboration with Celgene Corporation. Vividion will receive $101 million in upfront and equity consideration. The multi-year collaboration will focus on the identification and development of small molecules that function through the ubiquitin proteasome system, modulating specific protein levels for therapeutic benefit, against targets for a range of oncology, neurodegenerative and inflammatory indications.
  • Represented Editas Medicine, a leading genome editing company, in a strategic research and development alliance with Allergan Pharmaceuticals International Limited (a wholly-owned subsidiary of Allergan plc), under which Allergan received exclusive access and the option to license up to five of Editas’ genome-editing eye disease programs, including its lead program for Leber Congenital Amaurosis (LCA10), which is currently preclinical. Editas Medicine’s lead program is being developed for the potential treatment of LCA10—a rare, inherited retinal degenerative disease that appears in childhood and leads to blindness.
  • Represented Progress, the leading provider of application development and deployment technologies, in its $30 million acquisition of DataRPM, a privately held company and leader in cognitive predictive maintenance for the industrial IoT (IIoT) market. This acquisition is a key part of the Progress strategy to provide the best platform to build and deliver cognitive-first applications. We addressed complex intellectual property representations and IP deal structure issues on behalf of Progress.
  • Counseled Voyager Therapeutics, a clinical-stage gene therapy company, in a global strategic collaboration and option agreement with AbbVie to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Voyager Therapeutics will receive a $69 million upfront payment and potentially up to $155 million in preclinical and Phase 1 option payments as well as development and regulatory milestone payments and royalties.
  • Represented Panjiva, a global trade data company, in data licensing and distribution agreements with various customers and data partners.
  • Represented Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, in a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States, while Spark Therapeutics will continue to exclusively commercialize LUXTURNA™ (voretigene neparvovec-ryzl) in the US.
  • Represented Medtronic in the development of a standard warehouse agreement template and in the negotiation of a warehouse agreement with FedEx in the United States.
  • Represented Analog Devices in numerous joint development and collaboration agreements with companies in various technical markets which offer synergies to Analog.
  • Advised Blue Apron regarding intercompany technology and other services agreements. This work for Blue Apron is an extension of our role as the company’s main outside counsel, including advising Blue Apron on its recent initial public offering.
  • Represented Decibel Therapeutics in a strategic collaboration with Regeneron Pharmaceuticals to discover and develop new potential therapeutics to protect, repair and restore hearing.
  • Represented IronShore in an outsourcing and development agreement with Xuber.


  • Award Text

    Top Alliance 2017 Deal of the Year

    In Vivo


  • Award Text

    Technology Practice Group of the Year



  • Award Text

    Among the Best Firms in Massachusetts for Technology

    Chambers USA


  • Best Lawyers in America – Recognized 124 WilmerHale partners for 2020, naming eleven as “Lawyers of the Year,” including David Westenberg as Boston Technology Law Lawyer of the Year. 
  • Chambers Global – Recognized 34 WilmerHale lawyers and 27 practice areas, including our Life Sciences Practice, in its 2020 edition. Among those named “The World’s Leading Lawyers for Business” were Mark Borden and Jay Bothwick for corporate/M&A; Steve Singer for life sciences; and Robert Finkel for outsourcing.
  • Chambers USA: America’s Leading Lawyers for Business – Named our Corporate Practice among the best in 2012-2019, with sources saying that WilmerHale provides “excellent service and quality advice and representation.” The 2018 and 2019 editions of Chambers USA also ranked WilmerHale in the following regions and practices: Massachusetts and Washington DC for Corporate/M&A; Nationwide for Startups & Emerging Companies; and Massachusetts for Private Equity: Venture Capital Investment and Technology.
  • IAM Patent 1000 – Ranked WilmerHale a leading firm in 2018 for litigation nationally, as well as in California, Colorado, the DC Metro area and Massachusetts. The firm was also recommended in Massachusetts for its transactions practice.
  • In Vivo – Named Regeneron’s novel deal with Decibel Therapeutics, represented by WilmerHale, as the Top Alliance 2017 Deal of the Year.
  • Law360 – Named WilmerHale a Technology Practice Group of the Year for 2016–2019, an award recognizing the firm’s key role in the significant matters that made headlines and changed the legal landscape within the past year. 
  • LMG Life Sciences Named WilmerHale the Life Cycle Firm of the Year in 2017–2019, and awarded the firm a Finance and Transactional Impact Case of the Year Award in 2017 for counseling Editas Medicine in its licensing and collaboration with Allergan and a Hatch-Waxman Impact Case of the Year Award in 2018. LMG ranked the firm in its 2012-2019 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations, and previously named WilmerHale a Life Cycle Firm in 2012-2015. In 2013, WilmerHale was named the winner of the Canadian Impact Deals of the Year award, in recognition of its representation of Enobia Pharma in its acquisition by Alexion Pharmaceuticals, Inc.
  • The Legal 500 United States – Recommended WilmerHales mergers and acquisitions practice in the areas of antitrust, commercial deals and contracts, M&A middle-market, and venture capital and emerging companies in their 2010-2019 editions. Co-Chairs Steven Barrett and Belinda Juran are recommended for commercial deals and contracts as well as Michael Bevilacqua, Jeff Johnson, Steven Singer and Robert Finkel. “The ‘professional and ethical’ lawyers at WilmerHale ‘consistently deliver excellent results.’”
  • U.S. News - Best Lawyers® – In the 2010-2020 “Best Law Firms” rankings, our Corporate, Mergers and Acquisitions, and Venture Capital Practices were ranked in the first tier nationally and in Boston, along with our Corporate Practice also being ranked in the first tier in New York and Washington DC. Our Technology Practice was also ranked in the first tier in Boston and in the second tier nationally.

Insights & News